Market Overview

AVEO Oncology to Present at the Canaccord Genuity 38th Annual Growth Conference


AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey,
president and chief executive officer, will present at the Canaccord
Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8,
2018 at 4:30 p.m. Eastern Time.

A live webcast of the presentation can be accessed by visiting the
investors section of the Company's website at
A replay of the webcast will be archived for 30 days following the
presentation date.

About AVEO

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted medicines for oncology and other
areas of unmet medical need. The Company's strategy is to retain North
American rights to its oncology portfolio while securing partners in
development and commercialization outside of North America. The Company
is working to develop and commercialize its lead candidate tivozanib in
North America as a treatment for renal cell carcinoma. The Company has
outlicensed tivozanib (FOTIVDA®) for oncological indications
in Europe and other territories outside of North America, and it is
approved in the European Union, as well as Norway and Iceland, for the
first-line treatment of adult patients with advanced RCC and for adult
patients who are vascular endothelial growth factor receptor and mTOR
pathway inhibitor-naïve following disease progression after one prior
treatment with cytokine therapy for aRCC. The Company has entered into
partnerships to fund the development and commercialization of AV-203 and
ficlatuzumab, both clinical stage assets in oncology. The Company is
currently seeking a partner to develop the AV-353 platform, a
preclinical asset, worldwide for the potential treatment of pulmonary
arterial hypertension. The Company previously partnered with Novartis
International Pharmaceutical Ltd. to develop the AV-380 program in
cachexia and other indications, but Novartis has notified us that it is
terminating the collaboration without cause. Accordingly, effective
August 28, 2018 the Company expects to regain the rights to AV-380 and
is considering a variety of options to continue the program's
development. For more information, please visit the Company's website at

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO that
involve substantial risks and uncertainties. All statements, other than
statements of historical fact, contained in this press release are
forward-looking statements. Actual results or events could differ
materially due to a number of important factors, including risks
discussed in the section titled "Risk Factors" in AVEO's most recent
Annual Report on Form 10-K, its quarterly reports on Form 10-Q and its
other filings with the SEC. The forward-looking statements in this press
release represent AVEO's views as of the date of this press
release. AVEO anticipates that subsequent events and developments may
cause its views to change. While AVEO may elect to update these
forward-looking statements at some point in the future, it specifically
disclaims any obligation to do so. You should, therefore, not rely on
these forward-looking statements as representing AVEO's views as of any
date other than the date of this press release.

View Comments and Join the Discussion!